

Association between immune-related side effects and efficacy of checkpoint inhibitors – A systematic review and meta-analysis

Cancer Treatment Reviews

92, 102134

DOI: [10.1016/j.ctrv.2020.102134](https://doi.org/10.1016/j.ctrv.2020.102134)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Association between Immune Related Adverse Events and Outcome in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. <i>Cancers</i> , 2021, 13, 860.	1.7	37
3	Adrenal insufficiency development during chemotherapy plus anti-programmed death receptor-1 monoclonal antibody (tislelizumab) therapy in patients with advanced gastric cancer: two case reports. <i>Yeungnam University Journal of Medicine</i> , 2022, 39, 62-66.	0.7	3
4	Frequency of pre-treatment may not increase the immune-related adverse events of RCC patients treated with nivolumab. <i>Medicine (United States)</i> , 2021, 100, e25402.	0.4	2
5	Comprehensive analysis of tumor microenvironment and identification of an immune signature to predict the prognosis and immunotherapeutic response in lung squamous cell carcinoma. <i>Annals of Translational Medicine</i> , 2021, 9, 569-569.	0.7	4
6	Different Apples, Same Tree: Visualizing Current Biological and Clinical Insights into CTLA-4 Insufficiency and LRBA and DEF6 Deficiencies. <i>Frontiers in Pediatrics</i> , 2021, 9, 662645.	0.9	15
7	Development of immunity-related adverse events correlates with baseline clinical factors, survival and response to anti-PD-1 treatment in patients with inoperable or metastatic melanoma. <i>Journal of Dermatological Treatment</i> , 2022, 33, 2168-2174.	1.1	5
8	Adverse events during immunotherapy in Slovenian patients with metastatic melanoma reveal a positive correlation with better treatment outcomes. <i>Radiology and Oncology</i> , 2021, 55, 354-361.	0.6	5
9	Immunotherapy retreatment: case report, review of the literature and proposal for the definition of different scenarios. <i>Immunotherapy</i> , 2021, 13, 645-652.	1.0	2
10	Triple Combination Therapy With PD-1/PD-L1, BRAF, and MEK Inhibitor for Stage III&IV Melanoma: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 693655.	1.3	16
11	Prognostic Impact of Early Treatment Interruption of Nivolumab Plus Ipilimumab Due to Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma: A Multi-Institution Retrospective Study. <i>Targeted Oncology</i> , 2021, 16, 493-502.	1.7	6
12	Multidiscipline Immunotherapy-Based Rational Combinations for Robust and Durable Efficacy in Brain Metastases from Renal Cell Carcinoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6290.	1.8	4
13	Immune checkpoint inhibitors: current status. <i>BMJ Supportive and Palliative Care</i> , 2021, , bmjspcare-2021-002954.	0.8	1
14	Risk of selected gastrointestinal toxicities in metastatic renal cell carcinoma patients treated with immuno-TKI combinations: a meta-analysis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 1225-1232.	1.4	11
15	Integrative analysis of gut microbiome and host transcriptomes reveals associations between treatment outcomes and immunotherapy&induced colitis. <i>Molecular Oncology</i> , 2022, 16, 1493-1507.	2.1	17
16	Three-Dimensional Culture Models to Study Innate Anti-Tumor Immune Response: Advantages and Disadvantages. <i>Cancers</i> , 2021, 13, 3417.	1.7	14
17	Evaluating the efficacy and safety of immune checkpoint inhibitors by detecting the exposure-response: An inductive review. <i>International Immunopharmacology</i> , 2021, 97, 107703.	1.7	1
18	Eosinophil Count as Predictive Biomarker of Immune-Related Adverse Events (irAEs) in Immune Checkpoint Inhibitors (ICIs) Therapies in Oncological Patients. <i>Immuno</i> , 2021, 1, 253-263.	0.6	11
19	Immune-Related Adverse Events Associated With Outcomes in Patients With NSCLC Treated With Anti-PD-1 Inhibitors: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 708195.	1.3	16

#	ARTICLE	IF	CITATIONS
20	Recent strategies for nano-based PTT combined with immunotherapy: from a biomaterial point of view. <i>Theranostics</i> , 2021, 11, 7546-7569.	4.6	109
21	The Continuum of Thyroid Disorders Related to Immune Checkpoint Inhibitors: Still Many Pending Queries. <i>Cancers</i> , 2021, 13, 5277.	1.7	12
22	Prognostic impact of proton pump inhibitors for immunotherapy in advanced urothelial carcinoma. <i>BJUI Compass</i> , 2022, 3, 154-161.	0.7	13
23	Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2021, 39, 4073-4126.	0.8	580
24	Immunotherapy Monitoring with Immune Checkpoint Inhibitors Based on [18F]FDG PET/CT in Metastatic Melanomas and Lung Cancer. <i>Journal of Clinical Medicine</i> , 2021, 10, 5160.	1.0	20
25	Defining the correlation between immune-checkpoint inhibitors-related adverse events and clinical outcomes: a narrative review. <i>Ecancermedicalsecience</i> , 2021, 15, 1314.	0.6	1
26	Durable response after immunotherapy discontinuation for delayed and severe immune-related adverse event: a case report. <i>Immunotherapy</i> , 2021, 13, 1379-1386.	1.0	3
27	Clinical experience with CTLA-4 blockade for cancer immunotherapy: From the monospecific monoclonal antibody ipilimumab to probodies and bispecific molecules targeting the tumor microenvironment. <i>Pharmacological Research</i> , 2022, 175, 105997.	3.1	43
28	Bridging the Gap: Connecting the Mechanisms of Immune-Related Adverse Events and Autoimmunity Through PD-1. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 790386.	1.8	8
29	Complications following novel therapies for non-small cell lung cancer. <i>Journal of Internal Medicine</i> , 2022, 291, 732-754.	2.7	6
30	Associations between immune-related thyroid dysfunction and efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1795-1812.	2.0	31
31	Real World Outcomes versus Clinical Trial Results of Durvalumab Maintenance in Veterans with Stage III Non-Small Cell Lung Cancer. <i>Cancers</i> , 2022, 14, 614.	1.7	23
32	Immune-related adverse events are clinical biomarkers to predict favorable outcomes in advanced renal cell carcinoma treated with nivolumab plus ipilimumab. <i>Japanese Journal of Clinical Oncology</i> , 2022, 52, 479-485.	0.6	8
33	Cancer Immunotherapies: What the Perioperative Physician Needs to Know. <i>Current Oncology Reports</i> , 2022, 24, 399-414.	1.8	6
34	Monoclonal Antibodies to CTLA-4 with Focus on Ipilimumab. <i>Experientia Supplementum (2012)</i> , 2022, 113, 295-350.	0.5	3
35	Polymeric Systems for Cancer Immunotherapy: A Review. <i>Frontiers in Immunology</i> , 2022, 13, 826876.	2.2	12
36	Real-world 2-year long-term outcomes and prognostic factors in patients receiving nivolumab therapy for recurrent or metastatic squamous cell carcinoma of the head and neck. <i>Auris Nasus Larynx</i> , 2022, 49, 834-844.	0.5	5
37	Validation of an online application to identify potential immune-related adverse events associated with immune checkpoint inhibitors based on the patient's symptoms. <i>PLoS ONE</i> , 2022, 17, e0265230.	1.1	0

#	ARTICLE	IF	CITATIONS
38	Using Real-world Data to Define a Validated Nomogram for Advanced Bladder Cancer Patients Who Respond to Immunotherapy. <i>Clinical Oncology</i> , 2022, 34, 642-652.	0.6	5
39	Optimizing the prescription doses and tolerability of systemic therapy in head and neck cancer patients. <i>Current Opinion in Oncology</i> , 2022, Publish Ahead of Print, .	1.1	0
40	PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases. <i>Frontiers in Pharmacology</i> , 2022, 13, 854967.	1.6	10
41	Dropped head syndrome: a rare adverse drug reaction identified in the FDA adverse event reporting system and review of case reports in the literature. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 1329-1336.	1.0	4
42	An immune-related nomogram model that predicts the overall survival of patients with lung adenocarcinoma. <i>BMC Pulmonary Medicine</i> , 2022, 22, 114.	0.8	3
43	Can Immune-related adverse events serve as clinical biomarkers of PD-1/PD-L1 inhibitor efficacy in Pan-Cancer Patients?. <i>International Immunopharmacology</i> , 2022, 108, 108738.	1.7	1
44	Nobel Prize for immune checkpoint inhibitors, understanding the immunological switching between immunosuppression and autoimmunity. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 599-612.	1.0	1
45	Analysis of immune-mediated reactions in patients with non-small cell lung cancer treated with nivolumab and its association with effectiveness. <i>Journal of Oncology Pharmacy Practice</i> , 2023, 29, 290-298.	0.5	3
46	Clinicopathological implications of lncRNAs, immunotherapy and DNA methylation in lung squamous cell carcinoma: a narrative review. <i>Translational Cancer Research</i> , 2021, 10, 5406-5429.	0.4	4
47	Effects of immune checkpoint inhibitor therapy resumption in patients with malignant tumors after moderate-to-severe immune-related adverse events. <i>PLoS ONE</i> , 2022, 17, e0267572.	1.1	5
48	Salvage surgery after immune checkpoint inhibitors for advanced non-small cell lung cancer: potential association between immune-related adverse events and longer survival. <i>Clinical Lung Cancer</i> , 2022, , .	1.1	5
49	Treatment of patients with cancer using PD-1/PD-L1 antibodies: Adverse effects and management strategies (Review). <i>International Journal of Oncology</i> , 2022, 60, .	1.4	9
50	Role of radiomics in predicting immunotherapy response. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2022, 66, 575-591.	0.9	10
51	Acute generalized exanthematous pustulosis caused by gemcitabine after nivolumab in metastatic lung adenocarcinoma followed by a dramatic tumor response: A case report. <i>Thoracic Cancer</i> , 0, , .	0.8	4
52	Overview of Checkpoint Inhibitors Mechanism of Action: Role of Immune-Related Adverse Events and Their Treatment on Progression of Underlying Cancer. <i>Frontiers in Medicine</i> , 2022, 9, .	1.2	19
53	Prediction of Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors With a Panel of Autoantibodies: Protocol of a Multicenter, Prospective, Observational Cohort Study. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	7
54	A Prospective Study to Detect Immune Checkpoint Inhibitors Associated With Myocarditis Among Patients Treated for Lung Cancer. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, .	1.1	4
55	Five-year Follow-up of Patients With Head and Neck Cancer Treated With Nivolumab and Long-term Responders for Over Two Years. <i>In Vivo</i> , 2022, 36, 1881-1886.	0.6	3

#	ARTICLE	IF	CITATIONS
56	Immune Checkpoint Inhibitor-Associated Cardiotoxicity in Solid Tumors: Real-World Incidence, Risk Factors, and Prognostic Analysis. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	8
57	Predictive Biomarkers of Severe Immune-Related Adverse Events With Immune Checkpoint Inhibitors: Prevention, Underlying Causes, Intensity, and Consequences. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	3
58	Extracellular vesicle-based macromolecule delivery systems in cancer immunotherapy. <i>Journal of Controlled Release</i> , 2022, 348, 572-589.	4.8	10
59	Nivolumab and ipilimumab therapy in a patient with non-small cell lung cancer with chronic kidney disease. <i>Wspolczesna Onkologia</i> , 0, , .	0.7	0
60	Real World Study of Immune-Related Adverse Events Caused by PD-1 Inhibitors. <i>Advances in Clinical Medicine</i> , 2022, 12, 5913-5936.	0.0	0
61	Immunological markers for predicting the response to immunotherapy in non-small cell lung cancer. <i>Uspehi Molekularnoj Onkologii</i> , 2022, 9, 79-88.	0.1	0
62	Suspected immune checkpoint inhibitor-induced pulmonary sarcoid reaction in metastatic renal cell carcinoma. <i>Clinical Case Reports (discontinued)</i> , 2022, 10, .	0.2	1
63	Nivolumab for pediatric malignant peritoneal mesothelioma. <i>Pediatric Blood and Cancer</i> , 2023, 70, .	0.8	0
64	Inflammatory and autoimmune predictive markers of response to anti-PD-1/PD-L1 therapy in NSCLC and melanoma. <i>Experimental and Therapeutic Medicine</i> , 2022, 24, .	0.8	5
65	Expression Patterns of Necroptosis-Related Genes: Predicting Prognosis and Immunotherapeutic Effects in Cutaneous Melanoma. <i>Journal of Oncology</i> , 2022, 2022, 1-20.	0.6	0
66	Oncological Outcomes of Delayed Nephrectomy After Optimal Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma. <i>European Urology Oncology</i> , 2022, 5, 577-584.	2.6	19
67	Type 3 autoimmune pancreatitis (immune checkpoint inhibitor-induced pancreatitis). <i>Current Opinion in Gastroenterology</i> , 2022, 38, 516-520.	1.0	8
69	Immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer: A review. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
70	Immune-related adverse events in urothelial cancer patients: Adjustment for immortal time bias. <i>Cancer Science</i> , 2022, 113, 3912-3921.	1.7	4
71	Progress of CTLA-4 and PD-1 Immune Checkpoint Inhibitors in Treatment for Colorectal Cancer. , 0, 8, 569-575.		0
72	PD-1/PD-L1 Blockade in Cancer Immunotherapy: Clinical Benefits, Limitations and Beyond. , 0, 8, 84-93.		0
73	Combining radiation with immune checkpoint inhibitors therapy for HCC: From the alteration of the immune microenvironment by radiotherapy. <i>Radiation Medicine and Protection</i> , 2022, , .	0.4	1
74	Research Progress on Radiotherapy Combined with Immunotherapy for Associated Pneumonitis During Treatment of Non-Small Cell Lung Cancer. <i>Cancer Management and Research</i> , 0, Volume 14, 2469-2483.	0.9	5

#	ARTICLE	IF	CITATIONS
75	Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time bias. <i>Cancer Treatment Reviews</i> , 2022, 110, 102452.	3.4	19
76	Patients with melanoma treated with immune checkpoint inhibitors who had non-thyroid endocrine and skin immune-related adverse events have better prognosis: A systematic review and meta-analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
77	The role of gut microbiome in immune modulation in metastatic renal cell carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211227.	1.4	7
78	A successful case of transarterial chemoembolization for hyperprogressive disease induced by immunotherapy in a patient with unresectable hepatocellular carcinoma. <i>Clinical Journal of Gastroenterology</i> , 2022, 15, 1101-1107.	0.4	2
79	Thyroid-related adverse events induced by immune checkpoint inhibitors. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	9
80	COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis. , 2022, 10, e005111.		17
81	A case of cytokine release syndrome accompanied with COVID-19 infection during treatment with immune checkpoint inhibitors for non-small cell lung cancer. <i>Thoracic Cancer</i> , 2022, 13, 2911-2914.	0.8	6
82	Immune checkpoint inhibitor-induced hepatitis injury: risk factors, outcomes, and impact on survival. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 2235-2242.	1.2	4
83	Pancreatic injury following immune checkpoint inhibitors: A systematic review and meta-analysis. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	5
84	Immunotherapy combined with chemotherapy versus chemotherapy alone as the first-line treatment of PD-L1 negative and driver gene negative advanced nonsquamous non-small cell lung cancer: An updated systematic review and meta-analysis. <i>Thoracic Cancer</i> , 0, , .		5
85	Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases. <i>Nature Reviews Rheumatology</i> , 2022, 18, 641-656.	3.5	37
86	A Retrospective Cohort Study of Multiple Immune-Related Adverse Events and Clinical Outcomes Among Patients With Cancer Receiving Immune Checkpoint Inhibitors. <i>Cancer Control</i> , 2022, 29, 107327482211305.	0.7	4
87	Targeted Therapy and Immunotherapy in Melanoma. <i>Dermatologic Clinics</i> , 2023, 41, 65-77.	1.0	14
88	Peripheral absolute eosinophil count identifies the risk of serious immune-related adverse events in non-small cell lung cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
89	Association between skin immune-related adverse events (irAEs) and multisystem irAEs during PD-1/PD-L1 inhibitor monotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 1659-1666.	1.2	3
91	Evaluating liver function and the impact of immune checkpoint inhibitors in the prognosis of hepatocellular carcinoma patients: A systemic review and meta-analysis. <i>International Immunopharmacology</i> , 2023, 114, 109519.	1.7	2
92	Exploring genetic and immune underpinnings of the sexual dimorphism in tumor response to immune checkpoints inhibitors: A narrative review. <i>Current Research in Pharmacology and Drug Discovery</i> , 2023, 4, 100146.	1.7	1
94	Incidence rate and treatment strategy of immune checkpoint inhibitor mediated hepatotoxicity: A systematic review. , 2023, 1, 46-55.		1

#	ARTICLE	IF	CITATIONS
95	Immune-related adverse events are associated with therapeutic efficacy of immunotherapy in patients with melanoma brain metastases. <i>Melanoma Research</i> , 2023, 33, 58-65.	0.6	0
96	Immunotherapy for Melanoma: The Significance of Immune Checkpoint Inhibitors for the Treatment of Advanced Melanoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15720.	1.8	13
97	Nivolumab Hypersensitivity Reactions a Myth or Reality in Solid Tumors? A Systematic Review of the Literature. <i>Current Oncology</i> , 2022, 29, 9428-9436.	0.9	4
98	Macrophage renewal modes affect acquired resistance to gefitinib in EGFR mutant lung cancer PC9 cells. <i>Oncology Reports</i> , 2022, 49, .	1.2	1
99	Cutaneous, oral and genital lichenoid reactions associated with retifanlimab, a new PD-1 inhibitor. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2023, 37, .	1.3	2
100	Association of Immune-Related Adverse Events, Hospitalization, and Therapy Resumption With Survival Among Patients With Metastatic Melanoma Receiving Single-Agent or Combination Immunotherapy. <i>JAMA Network Open</i> , 2022, 5, e2245596.	2.8	15
101	Identifying Patients at Risk of Acute Kidney Injury among Patients Receiving Immune Checkpoint Inhibitors: A Machine Learning Approach. <i>Diagnostics</i> , 2022, 12, 3157.	1.3	6
102	Single-cell RNA sequencing reveals distinct T cell populations in immune-related adverse events of checkpoint inhibitors. <i>Cell Reports Medicine</i> , 2023, 4, 100868.	3.3	16
103	Pembrolizumab induced remission of recurrent and metastatic sinonasal squamous cell carcinoma after overcoming checkpoint inhibitor pneumonitis: A case report and literature review. <i>Cancer Reports</i> , 0, , .	0.6	3
104	Association of immune-related adverse events with the outcomes of immune checkpoint inhibitors in patients with dMMR/MSI-H metastatic colorectal cancer. , 2023, 11, e005493.		3
105	Nintedanib in an elderly non-small-cell lung cancer patient with severe steroid-refractory checkpoint inhibitor-related pneumonitis: A case report and literature review. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
106	Factors associated with liver injury and prognosis in advanced cancer patients treated with immune checkpoint inhibitors. <i>Hepatology Research</i> , 2023, 53, 450-459.	1.8	2
107	Immune checkpoint inhibitors and reproductive failures. <i>Journal of Reproductive Immunology</i> , 2023, 156, 103799.	0.8	11
108	Risk of Lichen Sclerosus and Lichen Planus in Patients Receiving Immune Checkpoint Inhibitors. <i>International Journal of Environmental Research and Public Health</i> , 2023, 20, 580.	1.2	4
110	Association Between Body Mass Index and Outcomes in Patients With Urothelial Carcinoma Treated With Pembrolizumab. <i>Anticancer Research</i> , 2023, 43, 269-274.	0.5	1
111	Management of Endocrine and Metabolic Toxicities of Immune-Checkpoint Inhibitors: From Clinical Studies to a Real-Life Scenario. <i>Cancers</i> , 2023, 15, 246.	1.7	8
112	Combined response of advanced cutaneous squamous cell carcinoma and renal cell carcinoma to immunotherapy: a case report. <i>Immunotherapy</i> , 2022, 14, 1419-1427.	1.0	1
113	Expresion paterns of various PDCD1 and PDL1 isoforms in prostate tumors. <i>Biopolymers and Cell</i> , 2022, 38, 169-185.	0.1	1

#	ARTICLE	IF	CITATIONS
114	A flexible liposomal polymer complex as a platform of specific and regulable immune regulation for individual cancer immunotherapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2023, 42, .	3.5	0
115	Molecular mechanism of Ganji Fang in the treatment of hepatocellular carcinoma based on network pharmacology, molecular docking and experimental verification technology. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	2
116	Association of immune-related adverse events and efficacy in advanced non-small-cell lung cancer: a systematic review and meta-analysis. <i>Immunotherapy</i> , 2023, 15, 209-220.	1.0	5
117	Efficacy and Safety of PD-1/PD-L1 Checkpoint Inhibitors versus Anti-PD-1/PD-L1 Combined with Other Therapies for Tumors: A Systematic Review. <i>Cancers</i> , 2023, 15, 682.	1.7	2
118	Survival and immunotoxicities in association with sex-specific body composition patterns of cancer patients undergoing immune-checkpoint inhibitor therapy â€“ A systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2023, 184, 151-171.	1.3	4
119	This month in JAAD Case Reports: April 2023: Immune checkpoint inhibitorâ€“associated novel cutaneous eruptions. <i>Journal of the American Academy of Dermatology</i> , 2023, 88, 788.	0.6	0
120	Comparison of Efficacy and Safety of First-Line Chemoimmunotherapy in Advanced Esophageal Squamous Cell Carcinoma: A Systematic Review and Network Meta-Analysis. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2023, 2023, 1-12.	0.7	2
121	Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Nonâ€“Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2023, 9, 527.	3.4	37
122	Imaging assessment of toxicity related to immune checkpoint inhibitors. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	6
123	Baseline risk factors associated with immune related adverse events and atezolizumab. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	3
124	Immune Checkpoint Inhibitors for Nasopharyngeal Carcinoma in a Real-world Setting in Japan. <i>In Vivo</i> , 2023, 37, 747-755.	0.6	1
125	Rheumatologic immune checkpoint inhibitor-related adverse events. <i>Current Opinion in Rheumatology</i> , 2023, 35, 141-148.	2.0	2
126	Systemic inflammatory syndromes as life-threatening side effects of immune checkpoint inhibitors: case report and systematic review of the literature. , 2023, 11, e005841.		12
127	Efficacy of immunotherapy in oncogene-driven non-small-cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, 175883592311614.	1.4	8
128	Prognostic Value of Absolute Lymphocyte Count in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab Plus Ipilimumab. <i>Journal of Clinical Medicine</i> , 2023, 12, 2417.	1.0	1
129	The impact of immunosuppressive agents on immune checkpoint inhibitor efficacy in patients with advanced melanoma: A realâ€“world, multicenter, retrospective study. <i>Cancer</i> , 2023, 129, 1885-1894.	2.0	2
130	Steroid Refractory Immune Checkpoint Induced Acute Interstitial Nephritis Salvaged by Mycophenolate Mofetil. , 2023, 2, .		0
131	A prognostic and immunotherapeutic predictive model based on the cell-originated characterization of tumor microenvironment in lung adenocarcinoma. <i>IScience</i> , 2023, 26, 106616.	1.9	0

#	ARTICLE	IF	CITATIONS
132	The surge of HBsAb level in a HBsAg-negative ES-SCLC patient after anlotinib plus atezolizumab treatment: A case report. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
133	Correlation of preclinical and clinical biomarkers with efficacy and toxicity of cancer immunotherapy. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, 175883592311638.	1.4	0
149	Diagnosis and Management of Dermatologic Adverse Events from Systemic Melanoma Therapies. <i>American Journal of Clinical Dermatology</i> , 0, , .	3.3	0
161	Complete pathologic response after laparoscopic hepatectomy following treatment with nivolumab and ipilimumab for anticancer drug-resistant MSI-high colon cancer liver metastasis consisting of poorly differentiated adenocarcinoma with squamous differentiation: A case report. <i>Clinical Journal of Gastroenterology</i> , 2024, 17, 57-64.	0.4	1
184	Clinical and translational attributes of immune-related adverse events. <i>Nature Cancer</i> , 0, , .	5.7	0